CR20210212A - Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico - Google Patents
Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínicoInfo
- Publication number
- CR20210212A CR20210212A CR20210212A CR20210212A CR20210212A CR 20210212 A CR20210212 A CR 20210212A CR 20210212 A CR20210212 A CR 20210212A CR 20210212 A CR20210212 A CR 20210212A CR 20210212 A CR20210212 A CR 20210212A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- methods
- receptor activation
- treating disorders
- disorders ameliorated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738333P | 2018-09-28 | 2018-09-28 | |
| PCT/US2019/053429 WO2020069301A1 (en) | 2018-09-28 | 2019-09-27 | Compositions and methods for treating disorders ameliorated by muscarnic receptor activation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210212A true CR20210212A (es) | 2021-09-24 |
Family
ID=69945518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210212A CR20210212A (es) | 2018-09-28 | 2019-09-27 | Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US10933020B2 (enExample) |
| EP (1) | EP3856182B1 (enExample) |
| JP (4) | JP7096441B2 (enExample) |
| KR (1) | KR102408292B1 (enExample) |
| CN (2) | CN115581696A (enExample) |
| AU (3) | AU2019346626B2 (enExample) |
| BR (1) | BR112021005802B1 (enExample) |
| CA (2) | CA3114623C (enExample) |
| CL (2) | CL2021000723A1 (enExample) |
| CO (1) | CO2021005261A2 (enExample) |
| CR (1) | CR20210212A (enExample) |
| EA (1) | EA202190356A1 (enExample) |
| IL (3) | IL295341B2 (enExample) |
| LT (1) | LT3856182T (enExample) |
| MX (1) | MX391629B (enExample) |
| NZ (1) | NZ773719A (enExample) |
| PH (1) | PH12021550616A1 (enExample) |
| SA (1) | SA521421595B1 (enExample) |
| SG (1) | SG11202102349PA (enExample) |
| UA (1) | UA128017C2 (enExample) |
| WO (1) | WO2020069301A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3061821B1 (en) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| MX391629B (es) | 2018-09-28 | 2025-03-21 | Karuna Therapeutics Inc | Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico |
| CN120478350A (zh) * | 2019-11-18 | 2025-08-15 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
| JP2024507367A (ja) * | 2021-02-24 | 2024-02-19 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための方法 |
| US20220370454A1 (en) * | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
| CN120535517A (zh) * | 2022-06-14 | 2025-08-26 | 南京迈诺威医药科技有限公司 | 占诺美林的帕莫酸盐、晶型及其制备方法和用途 |
| US12269818B2 (en) | 2023-04-24 | 2025-04-08 | Terran Biosciences Inc. | Analogs of xanomeline |
| WO2025167860A1 (zh) * | 2024-02-06 | 2025-08-14 | 南京迈诺威医药科技有限公司 | 一种含有占诺美林或其盐的药物组合物 |
| CN118267380B (zh) * | 2024-05-31 | 2024-08-27 | 北京普诺旺康医药科技有限公司 | 呫诺美林-曲司氯铵缓释微球胶囊及其制备方法 |
| WO2025255488A2 (en) | 2024-06-06 | 2025-12-11 | Karuna Therapeutics, Inc. | Xanomeline quercetin complexes and trospium salts |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647580A (en) | 1985-07-18 | 1987-03-03 | Syntex (U.S.A.) Inc. | Treatment of Alzheimer's disease |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| US5480651A (en) | 1992-03-16 | 1996-01-02 | Regents Of The University Of California | Composition and method for treating nicotine craving in smoking cessation |
| DE69430816T2 (de) * | 1993-08-19 | 2002-12-19 | Novo Nordisk A/S, Bagsvaerd | Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie |
| US5744476A (en) | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| DE19612504C2 (de) | 1996-03-29 | 2003-10-23 | Boehringer Ingelheim Kg | Neue Wirkstoffkompositionen |
| GB9612710D0 (en) | 1996-06-18 | 1996-08-21 | Pfizer Ltd | Method of treatment |
| EP0821956A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating disruptive behavior disorders |
| EP0821957A3 (en) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse |
| EP0821959A3 (en) | 1996-08-01 | 1998-09-16 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal |
| EP0821954A1 (en) | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Method for treating mental retardation |
| EP0821958A3 (en) | 1996-08-01 | 1998-07-08 | Eli Lilly And Company | Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression |
| DK0821955T3 (da) | 1996-08-01 | 2002-03-18 | Lilly Co Eli | Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse |
| AU5716898A (en) | 1997-01-08 | 1998-08-03 | Warner-Lambert Company | Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease |
| PL346247A1 (en) | 1998-08-18 | 2002-01-28 | Ucb Sa | Muscarinic agonists and antagonists |
| CN1396829A (zh) | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| US7084126B1 (en) | 2000-05-01 | 2006-08-01 | Healthpartners Research Foundation | Methods and compositions for enhancing cellular function through protection of tissue components |
| AU2001268055A1 (en) | 2000-06-30 | 2002-01-14 | Eli Lilly And Company | Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist |
| EP1352659A4 (en) | 2000-12-22 | 2004-06-30 | Takeda Chemical Industries Ltd | COMBINATION DRUGS |
| EP1357900A2 (en) | 2001-01-30 | 2003-11-05 | Board of Regents, The University of Texas System | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US20040023951A1 (en) | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
| WO2003030818A2 (en) | 2001-10-05 | 2003-04-17 | Pichit Suvanprakorn | Active agents using liposome beads |
| US20040224012A1 (en) | 2001-10-05 | 2004-11-11 | Pichit Suvanprakorn | Topical application and methods for administration of active agents using liposome macro-beads |
| US6887866B2 (en) * | 2002-01-25 | 2005-05-03 | Theravance, Inc. | Short-acting sedative hypnotic agents for anesthesia and sedation |
| WO2004060347A2 (en) | 2002-09-03 | 2004-07-22 | Transform Pharmaceuticals, Inc. | Pharmaceutical propylene glycol solvate compositions |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| MXPA04010921A (es) | 2002-05-03 | 2005-05-27 | Israel Inst Biolog Res | Metodos y composiciones para el tratamietno de trastornos del sistema nervioso central y periferico y compuestos novedosos utiles para los mismos. |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US20050250767A1 (en) | 2003-01-23 | 2005-11-10 | Weiner David M | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
| GB0307860D0 (en) | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
| WO2005044262A1 (en) * | 2003-10-29 | 2005-05-19 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
| ES2359375T3 (es) | 2003-11-04 | 2011-05-20 | Supernus Pharmaceuticals, Inc. | Formas de dosificación de dosis única diaria de trospio. |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| KR101157881B1 (ko) | 2003-12-22 | 2012-07-06 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 작용제로서의 아미노 치환된 디아릴［ａ,ｄ］사이클로헵텐 유사체, 및 신경정신 질환의 치료 방법 |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CA2582385A1 (en) | 2004-06-18 | 2005-12-18 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| GB0428170D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Mono and Combination Therapy |
| GB0428180D0 (en) | 2004-12-23 | 2005-01-26 | Biopartners Ltd | Combination therapy |
| US20060183733A1 (en) | 2005-02-11 | 2006-08-17 | Stephen Wills | Treating microvasculature diseases with acetyl cholinesterase inhibitors |
| JP4732769B2 (ja) | 2005-03-04 | 2011-07-27 | 富士フイルム株式会社 | 内視鏡装置 |
| TW200800959A (en) | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
| KR20080025079A (ko) | 2005-06-14 | 2008-03-19 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CN103142586A (zh) | 2005-09-02 | 2013-06-12 | 塞拉维达公司 | 治疗疾病的疗法 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0607949D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| GB0607952D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
| GB0607946D0 (en) | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| TW200811105A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ES2336275T3 (es) | 2006-05-04 | 2010-04-09 | Solvay Pharmaceuticals B.V. | Agonistas muscarinicos para tratar trastornos del control de impulsos. |
| US7905852B2 (en) | 2006-05-16 | 2011-03-15 | Barbara Jennings-Spring | Skin-contacting-adhesive free dressing |
| US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| US20100015184A1 (en) | 2006-12-13 | 2010-01-21 | Tuel Stephen M | Methods of Making Pharmaceutical Components for Customized Drug Products |
| GB0702385D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702416D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New combination |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0703999D0 (en) | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | New combination 667 |
| AU2008233232A1 (en) | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| WO2009003724A1 (en) * | 2007-07-03 | 2009-01-08 | Synthon B.V. | Tolterodine bead |
| WO2009036243A1 (en) | 2007-09-12 | 2009-03-19 | Glaxo Group Limited | Novel combination of therapeutic agents |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| NO2200610T3 (enExample) | 2007-09-21 | 2018-06-09 | ||
| CN102014877B (zh) | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| MX344177B (es) | 2008-03-27 | 2016-12-08 | Chase Pharmaceuticals Corp | Uso y composicion para tratar la demencia. |
| US20110119259A1 (en) | 2008-04-24 | 2011-05-19 | Trustees Of Boston University | Network biology approach for identifying targets for combination therapies |
| GB0822077D0 (en) | 2008-12-03 | 2009-01-07 | Minster Res Ltd | Novel treatments |
| AU2010221133A1 (en) | 2009-03-05 | 2011-09-22 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| US10265311B2 (en) * | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| EP3061821B1 (en) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| CA2786716A1 (en) * | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
| SG174658A1 (en) | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
| US20120289529A1 (en) * | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of trospium and salivary stimulants for the treatment of overactive bladder |
| CA2835293C (en) | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| US20130289019A1 (en) | 2012-04-26 | 2013-10-31 | Amazing Grace, Inc. | Methods of treating behaviorial and/or mental disorders |
| CN104768540A (zh) | 2012-09-05 | 2015-07-08 | 才思制药公司 | 抗胆碱能神经保护组合物和方法 |
| EP3265067A4 (en) | 2015-03-06 | 2018-09-12 | Chase Pharmaceuticals Corporation | Oxybutynin-xanomeline transdermal therapeutic system combinations |
| US10307409B2 (en) * | 2015-03-06 | 2019-06-04 | Chase Pharmaceuticals Corporation | Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system |
| US20180050018A1 (en) | 2015-03-06 | 2018-02-22 | Chase Pharmaceuticals Corporation | Peripheral-anticholinergic muscarinic agonist combination |
| JP6566254B2 (ja) | 2015-08-21 | 2019-08-28 | セイコープレシジョン株式会社 | フォーカルプレーンシャッタおよび光学機器 |
| HK1258048A1 (zh) | 2015-09-01 | 2019-11-01 | First Wave Bio, Inc. | 用於治疗与异常炎症反应相关的病症的方法和组合物 |
| EP3347012A4 (en) | 2015-09-11 | 2019-04-17 | Chase Pharmaceuticals Corporation | MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM |
| CL2018000559A1 (es) | 2015-10-14 | 2018-08-17 | First Wave Bio Inc | Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales |
| CN108697688A (zh) | 2016-01-20 | 2018-10-23 | 塞拉维达公司 | 用于治疗多汗症的方法和组合物 |
| WO2017147104A1 (en) | 2016-02-24 | 2017-08-31 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combinations |
| MX391629B (es) | 2018-09-28 | 2025-03-21 | Karuna Therapeutics Inc | Composiciones y metodos para tratar trastornos mejorados por medio de activacion de receptor muscarinico |
| US20210145804A1 (en) | 2019-11-18 | 2021-05-20 | Karuna Therapeutics, Inc. | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation |
| CN120478350A (zh) | 2019-11-18 | 2025-08-15 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
| JP2024507367A (ja) | 2021-02-24 | 2024-02-19 | カルナ セラピューティックス，インコーポレイテッド | ムスカリン受容体活性化によって改善される障害を処置するための方法 |
| US20220370454A1 (en) | 2021-05-18 | 2022-11-24 | Karuna Therapeutics, Inc. | Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics |
-
2019
- 2019-09-27 MX MX2021003621A patent/MX391629B/es unknown
- 2019-09-27 EA EA202190356A patent/EA202190356A1/ru unknown
- 2019-09-27 UA UAA202100847A patent/UA128017C2/uk unknown
- 2019-09-27 IL IL295341A patent/IL295341B2/en unknown
- 2019-09-27 CA CA3114623A patent/CA3114623C/en active Active
- 2019-09-27 CA CA3180743A patent/CA3180743A1/en active Pending
- 2019-09-27 CN CN202211404315.3A patent/CN115581696A/zh active Pending
- 2019-09-27 BR BR112021005802-8A patent/BR112021005802B1/pt active IP Right Grant
- 2019-09-27 AU AU2019346626A patent/AU2019346626B2/en active Active
- 2019-09-27 KR KR1020217011501A patent/KR102408292B1/ko active Active
- 2019-09-27 WO PCT/US2019/053429 patent/WO2020069301A1/en not_active Ceased
- 2019-09-27 SG SG11202102349PA patent/SG11202102349PA/en unknown
- 2019-09-27 NZ NZ773719A patent/NZ773719A/en unknown
- 2019-09-27 IL IL314873A patent/IL314873A/en unknown
- 2019-09-27 US US16/585,532 patent/US10933020B2/en active Active
- 2019-09-27 JP JP2021542064A patent/JP7096441B2/ja active Active
- 2019-09-27 CN CN201980064585.4A patent/CN112789042A/zh active Pending
- 2019-09-27 LT LTEPPCT/US2019/053429T patent/LT3856182T/lt unknown
- 2019-09-27 EP EP19865548.2A patent/EP3856182B1/en active Active
- 2019-09-27 CR CR20210212A patent/CR20210212A/es unknown
- 2019-09-27 IL IL281809A patent/IL281809B/en unknown
-
2020
- 2020-05-21 US US16/880,600 patent/US10925832B2/en active Active
-
2021
- 2021-01-07 US US17/143,904 patent/US11471413B2/en active Active
- 2021-02-04 US US17/167,714 patent/US20210154146A1/en not_active Abandoned
- 2021-03-18 PH PH12021550616A patent/PH12021550616A1/en unknown
- 2021-03-23 CL CL2021000723A patent/CL2021000723A1/es unknown
- 2021-03-28 SA SA521421595A patent/SA521421595B1/ar unknown
- 2021-05-05 CO CONC2021/0005261A patent/CO2021005261A2/es unknown
- 2021-11-30 CL CL2021003180A patent/CL2021003180A1/es unknown
-
2022
- 2022-02-03 US US17/649,826 patent/US11452692B2/en active Active
- 2022-02-09 JP JP2022018362A patent/JP7433351B2/ja active Active
- 2022-08-29 US US17/822,872 patent/US11890378B2/en active Active
- 2022-09-01 AU AU2022224813A patent/AU2022224813B2/en active Active
-
2023
- 2023-12-01 JP JP2023203693A patent/JP7676512B2/ja active Active
- 2023-12-21 US US18/392,891 patent/US20240238205A1/en active Pending
-
2024
- 2024-11-29 AU AU2024267020A patent/AU2024267020A1/en active Pending
-
2025
- 2025-04-30 JP JP2025075156A patent/JP2025118730A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210212A (es) | Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico | |
| CL2018002991A1 (es) | Formulaciones de un inhibidor de lsd1. | |
| CO2018005370A2 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| BR112015024530A2 (pt) | composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto | |
| MX2017006832A (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos. | |
| NI201200120A (es) | Derivados de fumarato de ácido graso y sus usos. | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| DOP2017000071A (es) | Terapia de combinación para alzheimer que usa anticuerpos anti-n3pglu a beta mas un inhibidor de bace. | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2014000129A (es) | Combinaciones de farmacos y su usos en el tratamiento de una condicion de tos. | |
| CU20150020A7 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| BR112014000423A2 (pt) | "composição de pasta dental, método para melhorar a higiene oral e uso de uma composição de pasta dental" | |
| CR11285A (es) | Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma | |
| CO2020004669A2 (es) | Derivados de bencimidazol y sus usos | |
| PL3937902T3 (pl) | Farmaceutyczna forma dawkowania do nakładania na błony śluzowe i sposób jej tworzenia | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| CO2019013589A2 (es) | Compuestos que contienen nitrógeno sustituido | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| UY36124A (es) | Derivados de carboxamida | |
| MX2018000264A (es) | Formulaciones topicas de diacereina de rheina y sus usos. | |
| MX2016015961A (es) | Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas. | |
| UY36123A (es) | Derivados de carboxamida |